A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants

An Open-Label, Single-Sequence Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole on the Pharmacokinetics of BMS-986165 in Healthy Participants

The purpose of this study is to evaluate the effects of stomach acid suppression by rabeprazole and BMS-986165 on how fast and complete the drug is absorbed into the body of healthy participants.

Inclusion Criteria

• Healthy participant, as determined by medical history, physical examination, ECGs, and clinical laboratory determinations
• Body mass index of 18.0 kilogram per meter square (kg/m^2) to 32.0 kg/m^2
• Normal renal function at screening as evidenced by an estimated glomerular filtration rate (GFR) greater than (>) 80 milliliter per minute per 1.732 meter square (mL/min/1.732 m^2)

Exclusion Criteria:

• Any major surgery within 4 weeks of study drug administration
• Use of any prescription drugs or over-the-counter acid controllers
• Positive urine screen for drugs of abuse, alcohol, or cotinine
• History of allergy to BMS-986165, rabeprazole, or related compounds

Other protocol inclusion/exclusion criteria may apply.